Neuroprotective Activity of Curcumin in Animal Models
A systematic review found that curcumin showed neuroprotective activity in preclinical models of Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic lateral sclerosis. However, over 80% of positive findings from animal studies have not been replicated in humans.
- Most relevant to
- Neurologist, Pharmacologist
Why it matters
This highlights potential therapeutic avenues but underscores the challenges in translating animal research to clinical applications. Understanding curcumin's mechanisms could lead to better treatments for neurodegenerative diseases.
What this does not prove
The findings are limited by incomplete formulation characterization, lack of CNS-exposure biomarkers in trials, and significant discrepancies between animal and human studies.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-06
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Neuroprotection, Other
Original sources
- Primary evidenceCurcumin's Potential in Neurodegenerative Diseases ↗
Supporting passages (6)
study phaseThe review is organized around five complementary thematic areas selected to span the full translational pipeline of curcumin in neurodegeneration, from mechanistic rationale to clinical applicability: (1) molecular mechanisms, addressing the pleiotropic activities that justify therapeutic interest; (2) pharmacokinetic barriers, the principal obstacle to clinical translation; (3) the evolution of drug delivery systems (DDSs), documenting the technological strategies developed to overcome these barriers; (4) disease-specific applications, evaluating the available evidence across the four main NDs; and (5) translational limitations, identifying the methodological and regulatory gaps that must be closed to enable clinical implementation.
study designThis is a narrative, non-systematic review of PubMed/MEDLINE, Scopus, and Web of Science.
research categoriesThe review is organized around five complementary thematic areas selected to span the full translational pipeline of curcumin in neurodegeneration, from mechanistic rationale to clinical applicability: (1) molecular mechanisms, addressing the pleiotropic activities that justify therapeutic interest; (2) pharmacokinetic barriers, the principal obstacle to clinical translation; (3) the evolution of drug delivery systems (DDSs), documenting the technological strategies developed to overcome these barriers; (4) disease-specific applications, evaluating the available evidence across the four main NDs; and (5) translational limitations, identifying the methodological and regulatory gaps that must be closed to enable clinical implementation.
findingsResults: Curcumin exhibits neuroprotective activity in preclinical models of the four NDs analysed, acting on six interconnected mechanisms and the gut-brain axis.
limitationsHowever, clinical translation remains limited: over 80% of positive animal findings have not been replicated in humans, formulation characterization is frequently incomplete, and most trials lack CNS-exposure biomarkers.
publication datePublication date: 2026-09-06
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.